Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry‐Based Cohort Study
The Oncologist is a journal devoted to medical and practice issues for surgical, radiation, and medical oncologists.
Related Articles
Biweekly dosing of trifluridine-tipiracil reduces rates of myelosuppression while maintaining efficacy in patients with metastatic colorectal cancer
AbstractBackground. Trifluridine-tipiracil (TAS-102) is approved as monotherapy and in combination with bevacizumab for refractory unresectable metastatic
A phase 0, window of opportunity study of parasympathetic stimulation with bethanechol in localized pancreatic adenocarcinoma prior to surgery
AbstractBackground. The parasympathetic branch of the autonomic nervous system has shown tumor-suppressive effects in preclinical models of pancreatic aden
A phase II, multicenter, single-arm study of pemigatinib in patients with metastatic or unresectable colorectal cancer harboring FGFR alterations
AbstractBackground. FGFR alterations are known to be driver alterations in several tumor types. We aimed to assess the efficacy of pemigatinib, an oral FGF
Incidence of patient-reported fatigue developing on palbociclib and endocrine therapy for advanced HR+ HER2− breast cancer
AbstractObjectives. Fatigue is a common nonhematologic toxicity of the CDK4/6 inhibitor palbociclib in metastatic breast cancer (MBC) patients with prevale
Anthracyclines-induced cardiotoxicity in patients with early breast cancer carrying germline BRCA1/2 mutation: the BRCAN study
AbstractBackground. BRCA1/2 genes play a critical role in genome stability and DNA repair. In animal models, loss of cardiomyocyte-specific BRCA1/2 is asso
Breast cancer incidence and mortality, by age, stage and molecular subtypes, by race/ethnicity in Canada
This article focuses on whether breast cancer characteristics and outcomes differ by race and ethnicity in Canada.
The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients
The development of immune-related adverse events (irAEs) has been associated with improved survival outcomes in non-small cell lung cancer (NSCLC). This st
Evaluation of a risk-sharing agreement for atezolizumab treatment in patients with non-small cell lung cancer: a strategy to improve access in low-income countries
This study focused on a prospective cost analysis conducted at a high-specialty health facility to assess the economic implications of implementing a risk-
Opioid use and adverse health effects in breast cancer survivors
This study examined opioid use and the risk of falls, fractures, lung problems, and cardiovascular events in breast cancer survivors in the years following
Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate
This article presents a case report for a patient who had received 3 lines of therapy for recurrent metastatic pancreatic cancer and who then underwent…